Deferiprone
Mild Alzheimer's Disease
Neuroscience Trials AustraliaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Mild Alzheimer's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT | Phase 4 | B |
Allogeneic Msc Longeveron Inc. | Phase 2 | B |
azd5213 AstraZeneca | Phase 2 | B |
AQW051 Novartis Pharmaceuticals | Phase 2 | CCC |
Lnk-754 Link Medicine Corporation | Phase 1 | CC |
Ionis Maptrx Ionis Pharmaceuticals, Inc. | Phase 1 | CC |
Dabigatran University of Rhode Island | Phase 1 | CC |
hpp854 High Point Pharmaceuticals, LLC. | Phase 1 | CC |
Same molecule, other indications
Deferiprone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →